<DOC>
	<DOC>NCT00807001</DOC>
	<brief_summary>This is a proof-of-concept study which will provide data about the safety and antiviral activity of several doses of the investigational drug IDX184 given for 3 days in treatment-naive HCV genotype 1-infected subjects so that optimal doses can be chosen for testing in later studies.</brief_summary>
	<brief_title>Double-Blind, Dose-Escalation Study of IDX184 in Chronic Hepatitis C Treatment-Naïve Subjects</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis, Chronic</mesh_term>
	<mesh_term>Hepatitis C, Chronic</mesh_term>
	<criteria>Inclusion criteria: 1. 1865 years old 2. Subject of childbearing potential must agree to use a consistent form of an acceptable doublebarrier method of birth control. 3. Plasma HCV RNA ≥ 5 log10 IU/mL 4. HCV genotype 1 Exclusion criteria: 1. Received prior antiviral treatment for hepatitis C infection 2. Subject is pregnant or breastfeeding 3. Body Mass Index (BMI) &gt; 32 4. Currently abusing alcohol or illicit drugs 5. Currently receiving methadone, buprenorphine or other drugs for the treatment of opioid addiction 6. Coinfected with hepatitis B virus (HBV, HBsAg positive) and/or human immunodeficiency virus (HIV)</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Hepatitis C, HCV, treatment-naive</keyword>
</DOC>